Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair Munro, Nick Andrews, Shuo Feng et al.|The Lancet Infectious Diseases|2022Cited by 180
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trialSaul N. Faust, DV Dung, Thomas Jaki et al.|The Lancet Child & Adolescent Health|2024Cited by 38
Procalcitonin-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection in the UK (BATCH): a pragmatic, multicentre, open-label, two-arm, individually randomised, controlled trialCherry-Ann Waldron, Philip Pallmann, Simon Schoenbuchner et al.|The Lancet Child & Adolescent Health|2025Cited by 14